Cocrystal Pharma, Inc. Logo

Cocrystal Pharma, Inc.

Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.

COCP | US

Overview

Corporate Details

ISIN(s):
US19188J4094
LEI:
Country:
United States of America
Address:
19805 N. CREEK PARKWAY, 98011 BOTHELL
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes its proprietary structure-based drug design technologies and Nobel Prize-winning expertise to create antiviral drugs that target the viral replication process. Its development pipeline includes candidates for the treatment of influenza, coronaviruses (including SARS-CoV-2), norovirus, and hepatitis C. Key programs in its portfolio are at various stages of clinical development, including a Phase 2 trial for an influenza A inhibitor (CC-42344) and a Phase 1 trial for a pan-viral protease inhibitor (CDI-988) targeting norovirus and coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cocrystal Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cocrystal Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cocrystal Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America
SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX
Seach Medical Group Ltd. Logo
Researches, cultivates, and produces certified medical cannabis oils and flowers for global markets.
Israel
SEMG
SEEGENE, INC. Logo
Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.
South Korea
096530
SEIKAGAKU CORPORATION Logo
A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.
Japan
4548

Talk to a Data Expert

Have a question? We'll get back to you promptly.